Crohn’s Disease: Basic Characteristics of the Disease, Diagnostic Methods, the Role of Biomarkers, and Analysis of Metalloproteinases: A Review
Abstract
:1. Introduction
2. Characteristics of Crohn’s Disease
2.1. Genetic Factors
2.2. Environmental Factors
2.3. Symptoms
- digestive system;
- osteoarticular system;
- circulatory system;
- the nervous system;
- excretory system;
- reproductive system.
2.4. Morphology
Molecular and Cellular Aspects of Crohn’s Disease
2.5. Criteria Used to Diagnose Crohn’s Disease and Differentiate It from Other Similar Diseases
2.6. Diagnostic Methods
2.6.1. Laboratory Examination of Blood and Stool
2.6.2. Histopathology
- loss of functioning of intestinal villi, the so-called projections that cover the mucosa of the small intestine. Their most important function is the digestion and absorption of food;
- inflammatory infiltrate;
- the presence of granulomas in the mucous membrane, i.e., a collection of bacterial cells with a spherical shape, participating in the immune response;
- uncontrolled growth of lymphatic follicles, i.e., lymphocytes, which constitute a protective barrier against microorganisms;
- appearance of fibrosis.
2.6.3. Endoscopy
2.6.4. X-ray
2.6.5. Computed Tomography
2.6.6. Ultrasonography
2.6.7. Magnetic Resonance Enterography
- thickness of the intestinal walls at the sinus [mm];
- degree of contrast enhancement (0–4 points);
- assessment of mural edema in T2-weighted fat-saturated sequences (0–4 points);
- assessment of the peri-mural T2 signal (0–4 points).
3. An Analysis of Matrix Metalloproteinases in Crohn’s Disease—The Role of Biomarkers
3.1. Characteristics of Matrix Metalloproteinases
3.2. Review of Studies Characterizing Metalloproteinases in Crohn’s Disease
4. Prognosis and Treatment of Crohn’s Disease
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- TChrzanowski, G.; Pasternak, G.; Aebisher, D.; Dynarowicz, K.; Myśliwiec, A.; Bartusik-Aebisher, D.; Sosna, B.; Cieślar, G.; Kawczyk-Krupka, A.; Filip, R. An Analysis of the Content of Metalloproteinases in the Intestinal Wall of Patients with Crohn’s Disease. Life 2023, 13, 2013. [Google Scholar] [CrossRef]
- de Souza, H.S.; Fiocchi, C. Immunopathogenesis of IBD: Current state of the art. Nat. Rev. Gastroenterol. Hepatol. 2016, 13, 13–27. [Google Scholar] [CrossRef] [PubMed]
- Mak, W.Y.; Zhao, M.; Ng, S.C.; Burisch, J. The epidemiology of inflammatory bowel disease: East meets west. J. Gastroenterol. Hepatol. 2020, 35, 380–389. [Google Scholar] [CrossRef]
- Matricon, J.; Barnich, N.; Ardid, D. Immunopathogenesis of inflammatory bowel disease. Self Nonself. 2010, 1, 4299–4309. [Google Scholar] [CrossRef]
- Roda, G.; Chien Ng, S.; Kotze, P.G.; Argollo, M.; Panaccione, R.; Spinelli, A.; Kaser, A.; Peyrin-Biroulet, L.; Danese, S. Crohn‘s disease. Nat. Rev. Dis. Primers 2020, 6, 22. [Google Scholar] [CrossRef] [PubMed]
- Khalil, H.; Ha, F. Crohn’s disease: A clinical update. Ther. Adv. Gastroenterol. 2015, 8, 352–359. [Google Scholar] [CrossRef]
- Laass, M.W.; Roggenbuck, D.; Conrad, K. Diagnosis and classification of Crohn’s disease. Autoimmun. Rev. 2014, 13, 467–471. [Google Scholar] [CrossRef]
- Actis, G.C.; Pellicano, R.; Fagoonee, S.; Ribaldone, D.G. History of Inflammatory Bowel Diseases. J. Clin. Med. 2019, 8, 111970. [Google Scholar] [CrossRef] [PubMed]
- Cromer, W.E.; Mathis, J.M.; Granger, D.N.; Chaitanya, G.V.; Alexander, J.S. Role of the endothelium in inflammatory bowel diseases. World J. Gastroenterol. 2011, 17, 5578–5593. [Google Scholar] [CrossRef]
- Coward, S.; Clement, F.; Williamson, T.; Hazlewood, G.; Ng, S.; Heitman, S.; Seow, C.; Panaccione, R.; Ghosh, S.; Kaplan, G.G. The rising burden of inflammatory bowel disease in North America from 2015 to 2025: A predictive model. Am. J. Gastroenterol. 2015, 110, S8292015. [Google Scholar] [CrossRef]
- Ng, S.C.; Shi, H.Y.; Hamidi, N.; Underwood, F.E.; Tang, W.; Benchimol, E.I.; Panaccione, R.; Ghosh, S.; Wu, J.C.Y.; Chan, F.K.L.; et al. Worldwide incidence and prevalence of inflammatory bowel dis-ease in the 21st century: A systematic review of population-based studies. Lancet 2017, 390, 2769–2778, Erratum in Lancet 2020, 396, 10256.e56. [Google Scholar] [CrossRef]
- da Silva, B.C.; Lyra, A.C.; Rocha, R.; Santana, G.O. Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis. World J. Gastroenterol. 2014, 20, 289458–289467. [Google Scholar] [CrossRef]
- Aniwan, S.; Santiago, P.; Loftus, E.V., Jr.; Park, S.H. The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries. United Eur. Gastro-Enterol. J. 2022, 10, 101063–101076. [Google Scholar] [CrossRef] [PubMed]
- Qin, X. Etiology of inflammatory bowel disease: A unified hypothesis. World J. Gastroenterol. 2012, 18, 151708–151722. [Google Scholar] [CrossRef] [PubMed]
- Aniwan, S.; Harmsen, W.S.; Tremaine, W.J.; Loftus, E.V., Jr. Incidence of inflammatory bowel disease by race and ethnicity in a population-based inception cohort from 1970 through 2010. Ther. Adv. Gastroenterol. 2019, 12, 1756284819827692. [Google Scholar] [CrossRef] [PubMed]
- Ek, W.E.; D’Amato, M.; Halfvarson, J. The history of genetics in inflammatory bowel dis-ease. Ann. Gastroenterol. 2014, 27, 294–303. [Google Scholar]
- Nayar, S.; Morrison, J.K.; Giri, M.; Gettler, K.; Chuang, L.S.; Walker, L.A.; Ko, H.M.; Kenigsberg, E.; Kugathasan, S.; Merad, M.; et al. A myeloid-stromal niche and gp130 rescue in NOD2-driven Crohn’s disease. Nature 2021, 593, 275–281. [Google Scholar] [CrossRef]
- Wang, M.H.; Picco, M.F. Crohn’s Disease: Genetics Update. Gastroenterol. Clin. N. Am. 2017, 46, 3449–3461. [Google Scholar] [CrossRef]
- Siddique, I.; Mustafa, A.S.; Khan, I.; Ziyab, A.H.; Altarrah, M.; Sulaiman, R.; Kadungothayil, N.; Shaheed, F. Detection of mutations in NOD2/CARD15 gene in Arab patients with Crohn’s disease. Saudi J. Gastroenterol. 2021, 27, 4240–4248. [Google Scholar] [CrossRef]
- Balestrieri, P.; Ribolsi, M.; Guarino, M.P.L.; Emerenziani, S.; Altomare, A.; Cicala, M. Nutritional Aspects in Inflammatory Bowel Diseases. Nutrients 2020, 12, 2372. [Google Scholar] [CrossRef]
- Pazmandi, J.; Kalinichenko, A.; Ardy, R.C.; Boztug, K. Early-onset inflammatory bowel disease as a model disease to identify key regulators of immune homeostasis mechanisms. Immunol. Rev. 2019, 287, 1162–1185. [Google Scholar] [CrossRef]
- Juliao-Baños, F.; Kock, J.; Arrubla, M.; Calixto, O.; Camargo, J.; Cruz, L.; Hurtado, J.; Clavijo, A.; Donado, J.; Schwartz, S.; et al. Trends in the epidemiology of inflammatory bowel disease in Colombia by demographics and region using a nationally representative claims database and characterization of inflammatory bowel disease phenotype in a case series of Colombian patients. Medicine 2021, 100, e24729. [Google Scholar] [CrossRef]
- Fontana, T.; Falco, N.; Torchia, M.; Tutino, R.; Gulotta, G. Bowel perforation in Crohn’s Disease: Correlation between CDAI and Clavien-Dindo scores. Il. G. Di. Chir. 2017, 38, 6303–6312. [Google Scholar] [CrossRef]
- Lakatos, P.L.; Lakatos, L. Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies. World J. Gastroenterol. 2008, 14, 253937–253947. [Google Scholar] [CrossRef] [PubMed]
- Huang, B.L.; Chandra, S.; Shih, D.Q. Skin manifestations of inflammatory bowel disease. Front. Physiol. 2012, 3, 13. [Google Scholar] [CrossRef] [PubMed]
- Dilauro, S.; Crum-Cianflone, N.F. Ileitis: When it is not Crohn’s disease. Curr. Gastroenterol. Rep. 2010, 12, 249–258. [Google Scholar] [CrossRef]
- Veauthier, B.; Hornecker, J.R. Crohn’s disease: Diagnosis and management. Am. Fam. Physician 2018, 98, 661–669. [Google Scholar]
- Villanacci, V.; Reggiani-Bonetti, L.; Salviato, T.; Leoncini, G.; Cadei, M.; Albarello, L.; Caputo, A.; Aquilano, M.C.; Battista, S.; Parente, P. Histopathology of IBD Colitis. A practical approach from the pathologists of the Italian Group for the study of the gastrointestinal tract (GIPAD). Pathologica 2021, 113, 139–153. [Google Scholar] [CrossRef] [PubMed]
- Fabián, O.; Kamaradová, K. Morphology of inflammatory bowel diseases (IBD). Cesk Patol. 2022, 58, 127–137. [Google Scholar]
- Ansar, W.; Ghosh, S. Inflammation and Inflammatory Diseases, Markers, and Mediators: Role of CRP in Some Inflammatory Diseases. Biol. C React. Protein Health Dis. 2016, 24, 67–107. [Google Scholar] [CrossRef]
- Guan, Q. A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease. J. Immunol. Res. 2019, 2019, 7247238. [Google Scholar] [CrossRef]
- Singh, R.; Balasubramanian, I.; Zhang, L.; Gao, N. Metaplastic Paneth Cells in Ex-tra-Intestinal Mucosal Niche Indicate a Link to Microbiome and Inflammation. Front. Physiol. 2020, 11, 280. [Google Scholar] [CrossRef] [PubMed]
- Bamias, G.; Pizarro, T.T.; Cominelli, F. Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease. Inflamm. Bowel Dis. 2022, 28, 3337–3349. [Google Scholar] [CrossRef]
- Gecse, K.B.; Bemelman, W.; Kamm, M.A.; Stoker, J.; Khanna, R.; Ng, S.C. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut 2014, 63, 1381–1392. [Google Scholar] [CrossRef]
- Bouma, G.; Strober, W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 2003, 3, 521–533. [Google Scholar] [CrossRef]
- Hendrickson, B.A.; Gokhale, R.; Cho, J.H. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin. Microbiol. Rev. 2002, 15, 79–94. [Google Scholar] [CrossRef] [PubMed]
- Beaugerie, L.; Seksik, P.; Nion-Larmurier, I.; Gendre, J.P. Predictors of Crohn‘s disease. Gastroenterology 2006, 130, 650–656. [Google Scholar] [CrossRef]
- Marzo, M.; Felice, C.; Pugliese, D.; Andrisani, G.; Mocci, G.; Armuzzi, A.; Guidi, L. Management of perianal fistulas in Crohn’s disease: An up-to-date review. World J. Gastroenterol. 2015, 21, 1394–1403. [Google Scholar] [CrossRef]
- Wasmann, K.A.; de Groof, E.J.; Stellingwerf, M.E.; D’Haens, G.R.; Ponsioen, C.Y.; Gecse, K.B. Treatment of perianal fistulas in Crohn’s disease, seton versus anti-TNF versus surgical closure following anti-TNF [PISA]: A randomised controlled trial. J. Crohns Colitis 2020, 14, 1049–1056. [Google Scholar] [CrossRef] [PubMed]
- Scharl, M.; Rogler, G. Pathophysiology of fistula formation in Crohn’s disease. World J. Gastrointest Pathophysiol. 2014, 5, 205–212. [Google Scholar] [CrossRef]
- Dongre, A.; Weinberg, R.A. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell Biol. 2019, 20, 69–84. [Google Scholar] [CrossRef] [PubMed]
- Magro, F.; Langner, C.; Driessen, A.; Ensari, A.; Geboes, K.; Mantzaris, G.J. European consensus on the histopathology of inflammatory bowel disease. J. Crohns Colitis 2013, 7, 827–851. [Google Scholar] [CrossRef]
- Annese, V.; Daperno, M.; Rutter, M.D.; Amiot, A.; Bossuyt, P.; East, J. European evidence based consensus for endoscopy in inflammatory bowel disease. J. Crohns Colitis 2013, 7, 982–1018. [Google Scholar] [CrossRef]
- Burisch, J.; Pedersen, N.; Čuković-Čavka, S.; Brinar, M.; Kaimakliotis, I.; Duricova, D.; Munkholm, P. East-west gradient in the incidence of inflammatory bowel disease in europe: The ECCO-EpiCom inception cohort. Gut 2014, 63, 588–597. [Google Scholar] [CrossRef]
- Seyedian, S.S.; Nokhostin, F.; Malamir, M.D. A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease. J. Med. Life 2019, 12, 2113–2122. [Google Scholar] [CrossRef]
- Feakins, R.M. Ulcerative colitis or crohn’s disease? pitfalls and problems. Histopathology 2014, 64, 317–335. [Google Scholar] [CrossRef]
- Dignass, A.; Lindsay, J.O.; Sturm, A.; Windsor, A.; Colombel, J.F.; Allez, M.; Van Assche, G. Second european evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: Current management. J. Crohns Colitis 2012, 6, 991–1030. [Google Scholar] [CrossRef] [PubMed]
- Dignass, A.; Van Assche, G.; Lindsay, J.O.; Lémann, M.; Söderholm, J.; Colombel, J.F. The second european evidence-based consensus on the diagnosis and management of crohn’s disease: Current management. J. Crohns Colitis 2010, 4, 28–62. [Google Scholar] [CrossRef]
- Tun, G.S.; Cripps, S.; Lobo, A.J. Crohn’s disease: Management in adults, children and young people—Concise guidance. Clin. Med. 2018, 18, 231–236. [Google Scholar] [CrossRef] [PubMed]
- Kornbluth, A.; Sachar, D.B. Ulcerative colitis practice guidelines in adults (update): American college of gastroenterology, practice parameters committee. Am. J. Gastroenterol. 2004, 99, 1371–1385. [Google Scholar] [CrossRef] [PubMed]
- LeBleu, V.S.; Taduri, G.; O’Connell, J.; Teng, Y.; Cooke, V.G.; Woda, C.; Sugimoto, H.; Kalluri, R. Origin and function of myofibroblasts in kidney fibrosis. Nat. Med. 2013, 19, 1047–1053. [Google Scholar] [CrossRef] [PubMed]
- Nuij, V.J.; Zelinkova, Z.; Rijk, M.C.; Beukers, R.; Ouwendijk, R.J.; Quispel, R.; Dutch Delta IBD Group. Phenotype of inflammatory bowel disease at diagnosis in the netherlands: A population-based inception cohort study (the delta cohort). Inflamm. Bowel Dis. 2013, 19, 2215–2222. [Google Scholar] [CrossRef] [PubMed]
- Abraham, B.P.; Mehta, S.; El-Serag, H.B. Natural history of pediatric-onset inflammatory bowel disease: A systematic review. J. Clin. Gastroenterol. 2012, 46, 581–589. [Google Scholar] [CrossRef] [PubMed]
- Henriksen, M.; Jahnsen, J.; Lygren, I.; Sauar, J.; Schulz, T.; Stray, N.; Ibsen Study Group. Change of diagnosis during the first five years after onset of inflammatory bowel disease: Results of a prospective follow-up study (the IBSEN study). Scand. J. Gastroenterol. 2006, 41, 1037–1043. [Google Scholar] [CrossRef] [PubMed]
- Okamoto, R.; Watanabe, M. Cellular and molecular mechanisms of the epithelial repair in IBD. Dig. Dis. Sci. 2005, 50 (Suppl. S1), S34–S38. [Google Scholar] [CrossRef] [PubMed]
- Kustosz, P.; Durlik, M. Molecular pathogenesis of Crohn’s disease. Prz. Gastroenterol. 2013, 8, 21–26. [Google Scholar] [CrossRef]
- Pai, R.K.; Jairath, V. What is the role of histopathology in the evaluation of disease activity in Crohn’s disease? Best Pract. Res. Clin. Gastroenterol. 2019, 38–39, 101601. [Google Scholar] [CrossRef]
- Bryant, R.V.; Winer, S.; Travis, S.P.; Riddell, R.H. Systematic review: Histological remission in inflammatory bowel disease. Is ‘complete’ remission the new treatment paradigm? An IOIBD initiative. J. Crohn’s Colitis 2014, 8, 1582–1597. [Google Scholar] [CrossRef]
- Liu, P.; Gao, C.; Chen, H.; Vong, C.T.; Wu, X.; Tang, X.; Wang, S.; Wang, Y. Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies. Acta Pharm. Sin B 2021, 11, 2798–2818. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Ren, J.A.; Wang, G.F.; Gu, G.S.; Wu, X.W.; Liu, S.; Ren, H.J.; Hong, Z.W.; Li, J.S. Impaired coagulation status in the Crohn’s disease patients complicated with intestinal fistula. Chin. Med. J. 2018, 131, 567–573. [Google Scholar] [CrossRef] [PubMed]
- Gao, S.Q.; Huang, L.D.; Dai, R.J.; Chen, D.D.; Hu, W.J.; Shan, Y.F. Neutrophil-lymphocyte ratio: A controversial marker in predicting Crohn’s disease severity. Int. J. Clin. Exp. Pathol. 2015, 8, 14779–14785. [Google Scholar] [PubMed]
- Vermeire, S.; Assche, G.V.; Rutgeerts, P. Laboratory markers in IBD: Useful, magic or unnecessary toys? Gut 2006, 55, 426–431. [Google Scholar] [CrossRef]
- Shabani, F.; Farasat, A.; Mahdavi, M.; Gheibi, N. Calprotectin (S100A8/S100A9): A key protein between inflammation and cancer. Inflamm. Res. 2018, 67, 801–812. [Google Scholar] [CrossRef]
- Manceau, H.; Chicha-Cattoir, V.; Puy, H.; Peoc’h, K. Fecal calprotectin in inflammatory bowel diseases: Update and perspectives. Clin. Chem. Lab. Med. 2017, 55, 474–483. [Google Scholar] [CrossRef] [PubMed]
- Sostegni, R.; Daperno, M.; Scaglione, N.; Lavagna, A.; Rocca, R.; Pera, A. Review article: Crohn’s disease: Monitoring disease activity. Aliment. Pharmacol. Ther. 2003, 17, 7–11. [Google Scholar] [CrossRef]
- de Oliveira, R.C.; Wilson, S.E. Fibrocytes, wound heating and corneal fibrosis. Investig. Ophthalmol. Vis. Sci. 2020, 61, 28. [Google Scholar] [CrossRef]
- Kiernan, M.G.; Coffey, J.C.; Sahebally, S.M.; Tibbitts, P.; Lyons, E.M.; O’leary, E.; Owolabi, F.; Dunne, C.P. Systematic Molecular Mediators of inflammation differentiate between Crohn’s disease and ulcerative colitis, implicating threshold levels of il-10 and relative ratios of pro-inflammatory cytokines in therapy. J. Crohn’s Colitis 2020, 14, 118–129. [Google Scholar] [CrossRef]
- Underwood, J.C. More than meets the eye: The changing face of histopathology. Histopathology 2017, 70, 4–9. [Google Scholar] [CrossRef]
- Ripollés, T.; Martínez- Peréz, M.J.; Blanc, E.; Delgado, F.; Vizuete, J.; Paredes, J.M.; Vilar, J. Contrast-enhanced ultrasound (CEUS) in Crohn’s disease: Technique, image interpretation and clinical application. Insights Imaging 2011, 2, 639–652. [Google Scholar] [CrossRef]
- Barnaś, E.; Ostańska, E.; Bartusik-Aebisher, D.; Dynarowicz, K.; Skręt-Magierło, J.; Aebisher, D. Breast cancer tissue treated using photodynamic therapy. Acta Pol. Pharm. Drug Res. 2021, 78, 835–843. [Google Scholar] [CrossRef]
- Aebisher, D.; Osuchowski, M.; Bartusik-Aebisher, D.; Krupka-Olek, M.; Dynarowicz, K.; Kawczyk-Krupka, A. An Analysis of the Effects of In Vitro Photodynamic Therapy on Prostate Cancer Tissue by Histopathological Examination and Magnetic Resonance Imaging. Int. J. Mol. Sci. 2022, 23, 1911354. [Google Scholar] [CrossRef] [PubMed]
- Geboes, K. Histopathology of Crohn’s disease and ulcerative colitis. Section 3: Diagnosis: A clinician’s perspective. Imflamm. Bowel Dis. 2003, 4, 255–276. [Google Scholar]
- Fabian, O.; Hradsky, O.; Potuznikova, K.; Kalfusova, A.; Krskova, L.; Hornofova, L.; Zamecnik, J.; Bronsky, J. Low predictive value of histopathological scoring system for complications development in children with Crohn’s disease. Pathol. Res. Pract. 2017, 213, 353–358. [Google Scholar] [CrossRef]
- Spiceland, C.M.; Lodhia, N. Endoscopy in inflammatory bowel disease: Role in diagnosis, management and treatment. World J. Gastroenterol. 2018, 24, 4014–4020. [Google Scholar] [CrossRef]
- Lescut, D.; Vanco, D.; Bonnière, P.; Lecomte-Houcke, M.; Quandalle, P.; Wurtz, A.; Colombel, J.F.; Delmotte, J.S.; Paris, J.C.; Cortot, A. Perioperative endoscopy of the whole small bowel in Crohn’s disease. Gut 1993, 34, 647–649. [Google Scholar] [CrossRef]
- Wilkins, T.; Jarvis, K.; Patel, J. Diagnosis and management of Crohn’s disease. Am. Fam. Physician 2011, 84, 1365–1375. [Google Scholar]
- Khanna, R.; Nelson, S.A.; Feagan, B.G.; D’Haens, G.; Sandborn, W.J.; Zou, G.Y.; MacDonald, J.K.; Parker, C.E.; Jairath, V.; Levesque, B.G. Endoscopic scoring indices for evaluation of disease activity in Crohn’s disease. Cochrane Database Syst. Rev. 2016, 2016, CD010642. [Google Scholar] [CrossRef]
- Stidham, R.W.; Cross, R.K. Endoscopy and cross-sectional imaging for assessing Crohn’s disease activity. Tech. Gastrointest. Endosc. 2016, 18, 123–130. [Google Scholar] [CrossRef]
- Ge, Z.Z.; Hu, Y.B.; Xiao, S.D. Capsule endoscopy in diagnosis of small bowel Crohn’s disease. World J. Gastroenterol. 2004, 10, 1349–1352. [Google Scholar] [CrossRef]
- Fireman, Z.; Mahajna, E.; Broide, E.; Shapiro, M.; Fich, L.; Sternberg, A.; Kopelman, Y.; Scapa, E. Diagnosing small bowel Crohn’s disease with wireless capsule endoscopy. Gut 2003, 52, 390–392. [Google Scholar] [CrossRef] [PubMed]
- Hudesman, D.; Mazurek, J.; Swaminath, A. Capsule endoscopy in Crohn’s disease: Are we seeing any better? World J. Gastroenterol. 2014, 20, 13044–13051. [Google Scholar] [CrossRef] [PubMed]
- Leighton, J.A.; Gralnek, I.M.; Richner, R.E.; Lacey, M.J.; Papatheofanis, F.J. Capsule endoscopy in suspected small bowel Crohn’s disease: Economic impact of disease diagnosis and treatment. World J. Gastroenterol. 2009, 15, 5685–5692. [Google Scholar] [CrossRef]
- Gatta, G.; Di Grezia, G.; Di Mizio, V.; Landolfi, C.; Mansi, L.; De Sio, I.; Rotondo, A.; Grassi, R. Crohn’s disease imaging: A review. Gastroenterol. Res. Pract. 2012, 2012, 816920. [Google Scholar] [CrossRef] [PubMed]
- Gourtsoyiannis, N.C.; Papanikolaou, N.; Karantanas, A. Magnetic resonance imaging evaluation of small intestinal Crohn’s disease. Best Pract. Res. Clin. Gastroenterol. 2006, 20, 137–156. [Google Scholar] [CrossRef]
- Dubcenco, E.; Jeejeebhoy, K.N.; Petroniene, R.; Tang, S.J.; Zalev, A.H.; Gardiner, G.W.; Baker, J. Capsule endoscopy findings in patients with established and suspected small-bowel Crohn’s disease: Correlation with radiologic, endoscopic and histologic findings. Gastrointest. Endosc. 2005, 62, 538–544. [Google Scholar] [CrossRef]
- Masselli, G.; Veccholi, A.; Gualdi, G.F. Crohn disease of the small bowel: MR enteroclysis versus conventional enteroclysis. Abdom. Imaging 2006, 31, 400–409. [Google Scholar] [CrossRef]
- Deepak, P.; Fletcher, J.G.; Fidler, J.L.; Bruining, D.H. Computed Tomography and Magnetic Resonance Enterography in Crohn’s disease: Assessment of Radiologic Criteria and Endpoints for Clinical Practice and Trials. Inflamm. Bowel Dis. 2016, 22, 2280–2288. [Google Scholar] [CrossRef]
- Zhang, T.; Fan, R.; Wang, Z.; Hu, S.; Zhang, M.; Lin, Y.; Tang, Y.; Zhong, J. Differential diagnosis between Crohn’s disease and intestinal tuberculosis using integrated parameters including clinical manifestations, T-SPOT, endoscopy and CT enterography. Int. J. Clin. Exp. Med. 2015, 8, 17578–17589. [Google Scholar]
- Zhao, X.S.; Wang, Z.T.; Wu, Z.Y.; Yin, Q.H.; Zhong, J.; Miao, F.; Yan, F.H. Differentiation of Crohn’s disease from intestinal tuberculosis by clinical and CT enterographic models. Inflamm. Bowel Dis. 2014, 20, 916–925. [Google Scholar] [CrossRef]
- Park, E.K.; Han, N.Y.; Park, B.J.; Sung, D.J.; Cho, S.B.; Jeen, Y.T.; Keum, B.; Kim, M.J. Value of Computerized Tomography Enterography in predicting Crohn’s disease activity: Correlation with Crohn’s disease activity index and C-reactive protein. Iran. J. Radiol. 2016, 13, e343012016. [Google Scholar] [CrossRef]
- Spinelli, A.; Allocca, M.; Jovani, M.; Danese, S. Review article: Optimal preparation for surgery in Crohn’s disease. Aliment. Pharmacol. Ther. 2014, 40, 1009–1022. [Google Scholar] [CrossRef] [PubMed]
- Sarno, A.; Varello, S.; Debani, P.; Bonenti, G.; Robotti, D. Intestinal ultrasonography in adults with Crohn’s disease: A 2020 update. Minerva Gastroenterol. E Dietol. 2019, 65, 335–345. [Google Scholar] [CrossRef] [PubMed]
- Casciani, E.; De Vincentiis, C.; Polettini, E.; Masselli, G.; Di Nardo, G.; Civitelli, F.; Cucchiara, S.; Gualdi, G.F. Imaging of the small bowel: Crohn’s disease in peadiatric patients. World J. Radiol. 2014, 6, 313–328. [Google Scholar] [CrossRef] [PubMed]
- Manetta, R.; Capretti, I.; Belleggia, N.; Marsecano, C.; Viscido, A.; Bruno, F.; Arrigoni, F.; Ma, L.; Guglielmi, G.; Splendiani, A.; et al. Magnetic resonance enterography (MRE) and ultrasonography (US) in the study of the small bowel in Crohn’s disease: State of the art and review of the literature. Acta Bio-Medica Atenei Parm. 2019, 90, 38–50. [Google Scholar] [CrossRef]
- Edwards, K.; Yearsley, K. Unusual presentation of Crohn’s disease. BMJ Case Rep. 2021, 14, e242703. [Google Scholar] [CrossRef] [PubMed]
- Dillman, J.R.; Smith, E.A.; Sanchez, R.J.; DiPietro, M.A.; DeMatos-Maillard, V.; Strouse, P.J.; Darge, K. Pediatric Small Bowel Crohn Disease: Correlation of US and MR Enterography. Radiographics 2015, 35, 835–848. [Google Scholar] [CrossRef] [PubMed]
- Yoon, K.; Chang, K.T.; Lee, H.J. MRI for Crohn’s Disease: Present and Future. BioMed. Res. Int. 2015, 2015, 786802. [Google Scholar] [CrossRef]
- Podgórska, J.; Pacho, R.; Albrecht, R. MR enterography imaging of Crohn’s disease in pediatric patients. Pol. J. Radiol. 2014, 79, 79–87. [Google Scholar] [CrossRef]
- D’Amico, F.; Chateau, T.; Laurent, V.; Danese, S.; Peyrin-Biroulet, L. Which MRI Score and Technique should be used for assessing Crohn’s disease activity? J. Clin. Med. 2020, 9, 1691. [Google Scholar] [CrossRef] [PubMed]
- Scharitzer, M.; Koizar, B.; Vogelsang, H.; Bergmann, M.; Primas, C.; Weber, M.; Schima, W.; Mang, T. Crohn’s disease: Prevalence, MR features and clinical significance of enteric and colonic sinus tracts. Eur. Radiol. 2020, 30, 5358–5366. [Google Scholar] [CrossRef]
- Pasternak, G.; Bartusik-Aebisher, D.; Aebisher, D.; Filip, F. Crohn’s disease—A case study. Eur. J. Clin. Exp. Med. 2021, 19, 93–97. [Google Scholar] [CrossRef]
- Mallya, S.K.; Mookhtiar, K.A.; Gao, Y.; Brew, K.; Dioszegi, M.; Birkedal-Hansen, H.; Van Wart, H.E. Characterization of 58-kilodalton human neutrophil collagenase: Comparison with human fibroblast collagenase. Biochemistry 1990, 29, 10628–10634. [Google Scholar] [CrossRef]
- Lovejoy, B.; Welch, A.R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R.T.; Browner, M.F. Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors. Nat. Struct. Biol. 1999, 6, 217–221. [Google Scholar] [PubMed]
- Fridman, R.; Fuerst, T.R.; Bird, R.E.; Hoyhtya, M.; Oelkuct, M.; Kraus, S.; Stetler-Stevenson, W.G. Domain structure of human 72-kDa gelati-nase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metallopro-teinase-2 (TIMP-2) binding regions. J. Biol. Chem. 1992, 267, 15398–15405. [Google Scholar] [CrossRef]
- Kaur, K.; Zhu, K.; Whittemore, M.S.; Petersen, R.L.; Lichte, A.; Tschesche, H.; Pourmotabbed, T. Identification of the active site of gelati-nase B as the structural element sufficient for converting a protein to a metalloprotease. Biochemistry 2002, 41, 4789–4797. [Google Scholar] [CrossRef] [PubMed]
- Becker, J.W.; Marcy, A.I.; Rokosz, L.L.; Axel, M.G.; Burbaum, J.J.; Fitzgerald, P.M.; Springer, J.P. Stromelysin-1: Three-dimensional structure of the inhibited catalytic domain and of the c-truncated proenzyme. Protein Sci. 1995, 4, 1966–1976. [Google Scholar] [CrossRef] [PubMed]
- Pavlovsky, A.G.; Williams, M.G.; Ye, Q.Z.; Ortwine, D.F.; Purchase, C.F.; White, A.D.; Blundell, T.L. X-Ray structure of human stromelysin catalytic domain complexed with nonpeptide inhibitors: Implications for inhibitor selectivity. Protein Sci. 1999, 8, 1455–1462. [Google Scholar] [CrossRef] [PubMed]
- Ganea, E.; Trifan, M.; Laslo, A.C.; Putina, G.; Cristescu, C. Matrix metalloproteinases: Useful and deleterious. Biochem. Soc. Trans. 2007, 35, 689–691. [Google Scholar] [CrossRef]
- Fernandez-Catalan, C.; Bode, W.; Huber, R.; Turk, D.; Calvete, J.J.; Lichte, A.; Maskos, K. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelati-nase a receptor. EMBO J. 1998, 17, 5238–5248. [Google Scholar] [CrossRef]
- PittaYAPruek, P.; Meephansan, J.; Prapapan, O.; Komine, M.; Ohtsuki, M. Role of matrix metalloproteinases in photoaging and photocarcinogenesis. Int. J. Mol. Sci. 2016, 17, 868. [Google Scholar] [CrossRef] [PubMed]
- Marchenko, G.N.; Strongin, A.Y. MMP-28, a new human matrix metalloproteinase with an unusual cysteine-switch sequence is widely expressed in tumors. Gene 2001, 265, 87–93. [Google Scholar] [CrossRef]
- Fischer, T.; Riedl, R. Challenges with matrix metalloproteinase inhibition and future drug discovery avenues. Expert Opin. Drug Discov. 2021, 16, 75–88. [Google Scholar] [CrossRef] [PubMed]
- Huang, H. Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances. Sensors 2018, 18, 3249. [Google Scholar] [CrossRef]
- Marônek, M.; Marafini, I.; Gardlík, R.; Link, R.; Troncone, E.; Monteleone, G. Metalloprotein-ases in Inflammatory Bowel Diseases. J. Inflamm. Res. 2021, 14, 1029–1041. [Google Scholar] [CrossRef]
- Warnaar, N.; Hofker, H.S.; Maathuis, M.H.; Niesing, J.; Bruggink, A.H.; Dijkstra, G.; Ploeg, R.J.; Schuurs, T.A. Matrix metalloproteinases as profibrotic factors in terminal ileum in Crohn’s disease. Inflamm. Bowel Dis. 2006, 12, 9863–9869. [Google Scholar] [CrossRef]
- Efsen, E.; Saermark, T.; Hansen, A.; Bruun, E.; Brynskov, J. Ramiprilate inhibits functional matrix metalloproteinase activity in Crohn’s disease fistulas. Basic Clin. Pharmacol. Toxicol. 2011, 109, 3208–3216. [Google Scholar] [CrossRef] [PubMed]
- Matusiewicz, M.; Neubauer, K.; Mierzchala-Pasierb, M.; Gamian, A.; Krzystek-Korpacka, M. Matrix metalloproteinase-9: Its interplay with angiogenic factors in inflammatory bowel diseases. Dis. Markers 2014, 2014, 643645. [Google Scholar] [CrossRef]
- Cervinková, M.; Horák, P.; Kanchev, I.; Matěj, R.; Fanta, J.; Sequens, R.; Kašpárek, P.; Sarnová, L.; Turečková, J.; Sedláček, R. Differential expression and processing of matrix metalloproteinase 19 marks progression of gastrointestinal diseases. Folia. Biol. 2014, 60, 113–122. [Google Scholar]
- Barberio, B.; D’Incà, R.; Facchin, S.; Dalla Gasperina, M.; Fohom Tagne, C.A.; Cardin, R.; Ghisa, M.; Lorenzon, G.; Marinelli, C.; Savarino, E.V.; et al. Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated with Infliximab. Inflamm. Bowel Dis. 2020, 26, 5756–5763. [Google Scholar] [CrossRef]
- Shamseya, A.M.; Hussein, W.M.; Elnely, D.A.; Adel, F.; Header, D.A. Serum matrix metalloproteinase-9 concentration as a marker of disease activity in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2021, 33 (Suppl. S1), e803–e809. [Google Scholar] [CrossRef] [PubMed]
- Gao, Q.; Meijer, M.J.; Kubben, F.J.; Sier, C.F.; Kruidenier, L.; van Duijn, W.; van den Berg, M.; van Hogezand, R.A.; Lamers, C.B.; Verspaget, H.W. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig. Liver Dis. 2005, 37, 8584–8592. [Google Scholar] [CrossRef] [PubMed]
- de Bruyn, M.; Vandooren, J.; Ugarte-Berzal, E.; Arijs, I.; Vermeire, S.; Opdenakker, G.B. The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases. Crit. Rev. Biochem. Mol. Biol. 2016, 51, 295–358. [Google Scholar] [CrossRef]
- de Almeida, L.G.N.; Thode, H.; Eslambolchi, Y.; Chopra, S.; Young, D.; Gill, S. Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology. Pharmacol. Rev. 2022, 74, 712–768. [Google Scholar] [CrossRef]
- O’Sullivan, S.; Gilmer, J.F.; Medina, C. Matrix metalloproteinases in inflammatory bowel disease: An update. Mediat. Inflamm 2015, 2015, 964131. [Google Scholar] [CrossRef]
- Hu, J.; Van den Steen, P.E.; Sang, Q.-X.A.; Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug. Discov. 2007, 6, 480–498. [Google Scholar] [CrossRef]
- Yoo, J.; Rodriguez Perez, C.E.; Nie, W.; Sinnett-Smith, J.; Rozengurt, E. Protein kinase D1 mediates synergistic MMP-3 expression induced by TNF-α and bradykinin in human colonic myofibroblasts. Biochem. Biophys Res. Commun. 2011, 413, 30–35. [Google Scholar] [CrossRef]
- Yagi, Y.; Andoh, A.; Inatomi, O.; Tsujikawa, T.; Fujiyama, Y. Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblasts. J. Gastroenterol. 2007, 42, 746–753. [Google Scholar] [CrossRef]
- Garg, P.; Rojas, M.; Ravi, A.; Bockbrader, K.; Epstein, S.; Vijay-Kumar, M.; Gewirtz, A.T.; Merlin, D.; Sitaraman, S.V. Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: Contrasting role of gelatinases in the pathogenesis of colitis. J. Immunol. 2006, 177, 4103–4112. [Google Scholar] [CrossRef] [PubMed]
- Levin, M.; Udi, Y.; Solomonov, I.; Sagi, I. Next generation matrix metalloproteinase inhibitors—Novel strategies bring new prospects. Biochim. Biophys Acta Mol. Cell. Res. 2017, 11 Pt A, 1927–1939. [Google Scholar] [CrossRef]
- Zucker, S.; Cao, J.; Chen, W.T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 2000, 19, 6642–6650. [Google Scholar] [CrossRef] [PubMed]
- Shi, Y.; Mam, X.; Fang, G.; Tian, X.; Ge, C. Matrix metalloproteinase inhibitors (MMPIS) as attractive therapeutic targets: Recent progress and current challenges. NanoImpact 2021, 21, 100293. [Google Scholar] [CrossRef]
- Winer, A.; Adams, S.; Mignatti, P. Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes. Mol. Cancer Ther. 2018, 17, 1147–1155. [Google Scholar] [CrossRef] [PubMed]
- Kessenbrock, K.; Plaks, V.; Werb, Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell 2010, 141, 52–67. [Google Scholar] [CrossRef] [PubMed]
- Torres, J.; Mehandru, S.; Colombel, J.F.; Biroulet, L.P. Crohn’s disease. Lancet 2017, 389, 1741–1755. [Google Scholar] [CrossRef] [PubMed]
- Freeman, H.J. Natural history and long-term clinical course of Crohn’s disease. World J. Gastroenterol. 2014, 20, 131–136. [Google Scholar] [CrossRef] [PubMed]
- Martínez Sánchez, E.R.; Solá Fernández, A.; Pérez Palacios, D.; Núñez Ortiz, A.; de la Cruz Ramírez, M.D.; Leo Carnerero, E.; Trigo Salado, C.; Herrera Justiniano, J.M. Perianal Crohn’s disease: Clinical implications, prognosis and use of resources. Rev. Esp. Enferm. Dig. 2022, 114, 5254–5258. [Google Scholar] [CrossRef]
Change | Evaluation | Point Verification |
---|---|---|
Degree of epithelial damage | Lack | 0 |
Focal change | 1 | |
Extensive changes | 2 | |
Structural changes | Natural | 0 |
Moderate | 1 | |
To a severe degree | 2 | |
Number of neutrophils in the lamina propria | The number is correct | 0 |
Moderate growth | 1 | |
Significant increase | 2 | |
Presence of neutrophils in the epithelium | Epithelial surface | 1 |
Inflammation | 2 | |
Abscesses | 3 | |
Ulcers | Occur | 0 |
Do not occur | 1 | |
Number of mononuclear cells in the lamina propria | The number is correct | 0 |
Moderate growth | 1 | |
Significant increase | 2 | |
Presence of ringworm | Occurs | 0 |
Absent | 1 | |
Percentage of biopsy fragments with inflammatory changes in the total material | 1 | |
2 | ||
3 |
Type of Change | Characteristics of the Analysis |
---|---|
Intra-abdominal abscesses | Presence of lesion, physiological assessment |
Strictures, fistulas | Determining the number |
Thickening of the intestinal wall | Assessment of the degree and extent of thickening |
Increased density of mesenteric fat | Physiological assessment |
Intestinal bleeding | Assessment of the extent of bleeding |
Strengthening the mucous membrane in the ileocecal area | Assessment of the change and its extent |
Ulcers | Extensiveness analysis |
Enlarged lymph nodes | Attendance assessment |
MMPs Name | Function |
---|---|
MMP-1 | inhibition of fibrosis |
MMP-2 | inhibition of angiogenesis, influence on the epithelial barrier function, inhibition of fibrosis |
MMP-3 | outflow to the production of Endostatin |
MMP-7 | alpha-defensin activation, chemokine expression, ulcer healing, Endostatin production |
MMP-8 | neutrophil infiltration |
MMP-9 | Chemokine expression, neutrophil infiltration, production of anti-angionenic factors, processing, VEGF-A activation, inhibition of goblet cell differentiation, inhibition of fibrosis |
MMP-10 | healing of ulcers |
MMP-13 | TNF-alpha activation and Endostatin production |
MMP-14 | ability to activate proMMP-2 |
MMP-15 | ability to activate proMMP-2 |
MMP-16 | ability to activate proMMP-2 |
MMP-17 | participation in the breakdown of the extracellular matrix, reproduction and tissue remodeling |
MMP-19 | Activity in the vessels of the synovial membrane |
MMP-20 | Endostatin production |
MMP-23 | presence in reproductive tissues |
MMP-24 | I group of membrane proteins |
MMP-25 | regulate innate immunity acting over proinflammatory cytokines, chemokines, and other immune-related proteins |
MMP-28 | wound healing |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pasternak, G.; Chrzanowski, G.; Aebisher, D.; Myśliwiec, A.; Dynarowicz, K.; Bartusik-Aebisher, D.; Sosna, B.; Cieślar, G.; Kawczyk-Krupka, A.; Filip, R. Crohn’s Disease: Basic Characteristics of the Disease, Diagnostic Methods, the Role of Biomarkers, and Analysis of Metalloproteinases: A Review. Life 2023, 13, 2062. https://doi.org/10.3390/life13102062
Pasternak G, Chrzanowski G, Aebisher D, Myśliwiec A, Dynarowicz K, Bartusik-Aebisher D, Sosna B, Cieślar G, Kawczyk-Krupka A, Filip R. Crohn’s Disease: Basic Characteristics of the Disease, Diagnostic Methods, the Role of Biomarkers, and Analysis of Metalloproteinases: A Review. Life. 2023; 13(10):2062. https://doi.org/10.3390/life13102062
Chicago/Turabian StylePasternak, Grzegorz, Grzegorz Chrzanowski, David Aebisher, Angelika Myśliwiec, Klaudia Dynarowicz, Dorota Bartusik-Aebisher, Barbara Sosna, Grzegorz Cieślar, Aleksandra Kawczyk-Krupka, and Rafał Filip. 2023. "Crohn’s Disease: Basic Characteristics of the Disease, Diagnostic Methods, the Role of Biomarkers, and Analysis of Metalloproteinases: A Review" Life 13, no. 10: 2062. https://doi.org/10.3390/life13102062